These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24452729)

  • 1. Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography.
    Tada T; Kastrati A; Byrne RA; Schuster T; Cuni R; King LA; Cassese S; Joner M; Pache J; Massberg S; Schömig A; Mehilli J
    Int J Cardiovasc Imaging; 2014 Mar; 30(3):495-504. PubMed ID: 24452729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
    Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT.
    Katayama Y; Kubo T; Akasaka T; Ino Y; Kimura K; Okura H; Shinke T; Igarashi K; Kadota K; Kozuma K; Tanabe K; Nakagawa Y; Muramatsu T; Morino Y; Kimura T;
    J Cardiol; 2017 Dec; 70(6):530-536. PubMed ID: 28536015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study.
    Koppara T; Tada T; Xhepa E; Kufner S; Byrne RA; Ibrahim T; Laugwitz KL; Kastrati A; Joner M
    Int J Cardiol; 2018 May; 258():42-49. PubMed ID: 29544956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial.
    Adriaenssens T; Ughi GJ; Dubois C; De Cock D; Onsea K; Bennett J; Wiyono S; Sinnaeve P; Coosemans M; Ferdinande B; Belmans A; D'hooge J; Desmet W
    EuroIntervention; 2016 Apr; 11(14):e1619-26. PubMed ID: 25420791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular response to drug-eluting stent with biodegradable vs. durable polymer. Optical coherence tomography substudy of the NEXT.
    Kubo T; Akasaka T; Kozuma K; Kimura K; Fusazaki T; Okura H; Shinke T; Ino Y; Hasegawa T; Takashima H; Takamisawa I; Yamaguchi H; Igarashi K; Kadota K; Tanabe K; Nakagawa Y; Muramatsu T; Morino Y; Kimura T;
    Circ J; 2014; 78(10):2408-14. PubMed ID: 25099476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.
    Lee DH; Park TK; Song YB; Chun WJ; Choi RK; Jeong JO; Im ES; Kim SW; Lee JM; Yang JH; Hahn JY; Choi SH; Choi JH; Lee SH; Gwon HC
    PLoS One; 2017; 12(8):e0183079. PubMed ID: 28797113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation acute myocardial infarction with two different everolimus-eluting stents: a randomized controlled trial of biodegradable versus durable polymer stents.
    Otake H; Ishida M; Nakano S; Higuchi Y; Hibi K; Kuriyama N; Iwasaki M; Kataoka T; Kubo T; Tsujita K; Ashikaga T; Shinke T; Itoh T; Kimura T; Morino Y;
    Cardiovasc Interv Ther; 2023 Jan; 38(1):75-85. PubMed ID: 35896895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: five-year follow-up optical coherence tomography study.
    Kuramitsu S; Sonoda S; Yokoi H; Iwabuchi M; Nishizaki Y; Shinozaki T; Domei T; Hyodo M; Inoue K; Shirai S; Ando K; Nobuyoshi M
    Atherosclerosis; 2014 Nov; 237(1):23-9. PubMed ID: 25190308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
    Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
    Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
    Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.
    Vlachojannis GJ; Puricel S; Natsuaki M; Morimoto T; Smits PC; Kimura T
    EuroIntervention; 2017 Mar; 12(16):1970-1977. PubMed ID: 27802927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
    Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of late-acquired stent malapposition of drug eluting stents with second generation permanent and biodegradable polymer coatings-A prospective, randomized comparison using optical coherence tomography.
    Roth C; Gangl C; Dalos D; Delle-Karth G; Neunteufl T; Berger R
    J Interv Cardiol; 2018 Dec; 31(6):780-791. PubMed ID: 30479028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial.
    Lee SY; Kim JS; Yoon HJ; Hur SH; Lee SG; Kim JW; Hong YJ; Kim KS; Choi SY; Shin DH; Nam CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1810-1819. PubMed ID: 29454763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.